June is Men’s Health Month in the USA and the third Sunday of June is celebrated as Father's Day. So in addition to Prostate Cancer Awareness Month in September and "Movember" (grow or wear a mustache in November to show you're "committed to changing the face of men’s health") June is a good time for health organizations to stand up for men. The College of American Pathologists (CAP) does so in an advisory, "5 Things to Know About Your PSA Test."
The pathologists' organization suggests that if you're a man "heeding the advice of your wife, girlfriend or significant other," you may have decided this June "to schedule yourself for that routine physical that you've been putting off. One aspect of your visit to the doctor’s office might be a PSA test."
Leading up to Father’s Day, a time when the focus is already on men and families, we can help raise awareness and funds to help protect men from prostate cancer - the most common cancer affecting men.
So please on June 19th join people across Canada and Wear Plaid for Dad. Whether it’s a shirt, a tie, a scarf, or even a suit – if it’s plaid it’ll work! With just a simple wardrobe choice, you’ll be helping protect the 1 in 8 men who will be diagnosed with prostate cancer in their lifetime.
Prostate cancer survivors during the era 2005-2013, as you'll see from our tag cloud (sidebar), were bombarded by Dendreon's controversial campaign to speed FDA approval of its immunotherapy vaccine Provenge. Since then, Provenge hype has calmed down, while the push for Abiraterone acetate (Zytiga) has heated up.
Abiraterone (generic name) aka Zytiga (brand name) is a high-powered castration drug FDA approved for use with 10-mg prednisone as a treatment for men with metastatic CRPC. Compared to Provenge, which costs around $90,000 for a course of treatment, Zyiga costs about $5,000 a month with expected follow-up doses for around eight months.
PSA Rising /DALLAS/ – July 25, 2011 – UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than previously was thought.
"We have recently discovered that castration resistant prostate cancer (CRPC) is unexpectedly driven by dihydrotestosterone synthesis from adrenal precursors in a pathway that circumvents testosterone," says Dr. Nima Sharifi, assistant professor of internal medicine and senior author of a study in Proceedings of the National Academy of Sciences. ...continue reading New Pathway to Potential Therapies for Advanced Prostate Cancer
Robot assisted prostate surgery, known medically as the da Vinci prostatectomy, has had a profound influence over treatment during the past decade. Robotic surgical technology was first developed by the military for use in the battlefield. However during the past decade, this technology has been rapidly applied to the general medical setting, notably in the field of prostate cancer. ...continue reading How does a robotic prostatectomy work?